{"id":"supportive-care-tacrolimus-ripertamab","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infection risk (from tacrolimus immunosuppression)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ripertamab functions as a bispecific antibody designed to bridge T cells and tumor cells, facilitating immune-mediated killing. Tacrolimus provides immunosuppressive support to manage immune-related complications. The combination with supportive care addresses clinical management of the underlying condition being treated.","oneSentence":"Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:56.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (investigational, Phase 3)"}]},"trialDetails":[{"nctId":"NCT06405100","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-05","conditions":"Minimal Change Disease","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Test group 1"],"phase":"phase_3","status":"active","brandName":"Supportive care+Tacrolimus+Ripertamab","genericName":"Supportive care+Tacrolimus+Ripertamab","companyName":"Air Force Military Medical University, China","companyId":"air-force-military-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression. Used for Hematologic malignancies (investigational, Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}